Mode
Text Size
Log in / Sign up
N/A N=305 Randomized Single-blind Treatment

Kids FACE FEARS Comparative Effectiveness Research

Child Anxiety · Anxiety Disorders · Anxiety · Anxiety Symptoms · Anxiety, Mild to Moderate

Enrolled (actual)
305
Serious AEs
0.0%
Results posted
Mar 2025
Primary outcome: Primary: Promis Pediatric Short Form v. 2.0-Anxiety (Parent Proxy/Caregiver Report) — 65.7; 66.0; 59.2; 59.1 T-Score

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Therapist-Led CBT (telehealth, office-based, or hybrid) (Behavioral); Guided Online CBT (Behavioral)
Age
Pediatric, Adult · 7+ yrs
Sex
All
Sponsor
Boston Medical Center
Primary completion
Apr 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Promis Pediatric Short Form v. 2.0-Anxiety (Parent Proxy/Caregiver Report)
65.7; 66.0; 59.2; 59.1; 57.9; 57.7
PRIMARY
Promis Pediatric Short Form v. 2.0-Anxiety (Pediatric/Youth Self-Report)
61.4; 61.2; 55.6; 56.4; 54.7; 54.4
PRIMARY
Child Anxiety Life Interference Scale (CALIS), Caregiver Report
26.3; 26.8; 20.2; 20.5; 18.9; 19.3
PRIMARY
Child Anxiety Life Interference Scale (CALIS), Youth Self-Report
13.1; 13.4; 10.6; 11.1; 10.6; 10.1
SECONDARY
Caregiver Treatment Satisfaction (Continuously Scored)
2.2; 2.7
SECONDARY
Caregiver Treatment Dissatisfaction (% of "Dissatisfied" Caregivers, Based on Dichotomous Coding of Dissatisfaction)
23.9; 6.8
SECONDARY
Youth Treatment Satisfaction (Continuously Scored)
2.1; 2.4
SECONDARY
Youth Treatment Dissatisfaction (% of "Dissatisfied" Youth, Based on Dichotomous Coding of Dissatisfaction)
33.3; 19.9
SECONDARY
Caregiver-Perceived Effectiveness
2.9; 4.2
SECONDARY
Rate of Treatment Responders (% of Children Whose Posttreatment PARS Score Was at Least 35% Less Than Their Baseline PARS Score)
48.7; 55.4
SECONDARY
Caregiver Homework Engagement (% of Weeks Caregiver Completed Assigned Homework)
53.1; 70.7
SECONDARY
Youth Homework Engagement (% of Weeks Youth Completed Assigned Homework)
50.8; 61.9
SECONDARY
Treatment Completion (% of Children Who Completed Their Treatment Program)
53.2; 46.3
SECONDARY
Treatment Comprehension Difficulties (Caregiver Report)
1.67; 1.01
SECONDARY
Difficulty Making Time for Treatment (Caregiver Report)
3.17; 2.14
SECONDARY
Treatment Discomfort (Caregiver Report)
2.81; 2.86

Summary

The Kids FACE FEARS (Kids Formats of Anxiety Care Effectiveness study For Extending the Acceptability and Reach of Services) is a large-scale, streamlined, pragmatic Randomized Controlled Trial (RCT) evaluating Therapist-Led CBT (telehealth, office-based, or hybrid) vs. Guided Online Cognitive-Behavioral Therapy (CBT) for the treatment of elevated child and adolescent anxiety. Families will be recruited from pediatric health centers serving primarily racial/ethnic minority youth in urban, suburban, and semi-rural regions. Services will be offered in English and Spanish. Patient-centered outcomes will be evaluated across a one-year follow-up period. To compare the effectiveness of the two treatment comparators, investigators will analyze the reports of caregivers, youth, and therapists, as well as independent evaluators who are not informed of each child's treatment assignment. Primary outcomes will focus on family-rated anxiety severity and impairment, treatment responder and remission status rated by independent evaluators, family-perceived effectiveness, and treatment satisfaction. Secondary analyses will examine additional outcomes, predictors of varied outcomes across different subgroups of youth, and facilitators and barriers to treatment implementation. Caregivers, patients, providers, and other key stakeholders will be actively engaged throughout all aspects of the research.

Eligibility Criteria

To maximize generalizability, inclusion criteria were wider and exclusion criteria were minimal compared to majority of previous RCTs of youth anxiety treatment

Inclusion Criteria

  • Children age 7-18 years at the time of screening
  • Child has elevated anxiety as indicated by a T-score above 55 (greater than 0.5 SD (Standard Deviation) above the mean) on the PROMIS Item Bank v2.0 - Anxiety - Short Form 8a (child self-report or parent proxy report) in English or Spanish at the time of screening
  • Child and caregiver(s) are fluent in English or Spanish
  • Child's parent or legal guardian is age 16 or older
  • If child taking SSRI/Pharmacotherapy for anxiety, must be on stable dose for greater than or equal to 8 weeks from the time of screening (self-reported, must be reported by parent if under the age of 18)
  • Receiving care at sites participating in the study

Exclusion Criteria

  • Severity requiring higher level of care, as indicated by any of the following: (a) suicidal thoughts or behaviors (STP) with an active plan; (b) STB(s) requiring higher level of care in the past 6 months; (c) anxiety-related absence > 50% of school days over the past month (if summer, the last month of school enrolled); (d) substance use that required emergency services or inpatient/partial hospitalization within past 3 months; or (e) clinician-determination that child requires higher level of care.
  • History of diagnosed autism spectrum disorder with severe challenges and needs for support (e.g., complete absence of verbal communication unrelated to anxiety), or intellectual disability with severe challenges or needs for support.
  • Currently engaged in CBT or planning to continue a non-study psychotherapy for anxiety during the time of the study (self-reported, must be reported by parent if under the age of 18)
  • Treatment participants not fluent in English or Spanish
  • Child is ward of the state
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03707158). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search